Imeglimin Hydrochloride: A Novel Approach to Type 2 Diabetes Management

Abstract

Imeglimin hydrochloride is an novel drug evolve for the treatment of type 2 diabetes mellitus. It is characterized by its unique mechanism of action, targeting both pancreatic beta cells and peripheral tissues to improve insulin secretion and sensitivity. Early clinical trials showed promise in reducing blood sugar levels, but further research was needed to determine its safety and effectiveness. Some reported side effects included gastrointestinal symptoms like nausea and diarrhea. The regulatory status of Imeglimin varied by region, and patients were advised to consult with healthcare professionals for the latest information on its availability and use. Validation of imeglimin hydrochloride and its enantiomers, drug release patterns of the nanofibers, comparing its impact with other available drug like metformin, method of action by targeting mitrocondria, pharmacokinetics and therapeutic effect of imeglimin hydrochloride, Imeglimin treatment, both short-and long-term, counteracts the metabolic syndrome's cardiorenal dysfunction, its Potential Ketoacidosis, its solubility and UV-Spectrophotometry. [1] INTRODUCTION:A novel molecule called imeglimin is being developed to treat type 2 diabetes. This medication belongs to the glimin class of glucose-lowering medications, making it the first of its kind in this category. Optimal glucose regulation is necessary in type 2 diabetes to correct anomalies in insulin responsiveness and release. Imeglimin operates through a distinctive mechanism of action, addressing three crucial pathophysiological aspects of type 2 diabetes: greater death of cells, increased hypergluconeogenesis, and decreased muscle tissue absorption of glucose. Recent stage II and phase III studies revealed imeglimin's efficacy for enhancing the level of glycated haemoglobin and fasting blood glucose (FPG) levels, either alone or in conjunction with other sugar-lowering medications. The rise of diabetes type 2 mellitus (T2DM) in the twenty-first century poses a serious medical, societal, and economic problem. The number of individuals with carbohydrate metabolism problems is growing, particularly among young people. By following the World Diabetes Federation (IDF), The global diabetic population is projected to rise from 463 million in 2019 to reach 700 million by the year 2045. T2DM is typically detected 10 years after the disease manifests itself, and a considerable proportion of people with it already have serious micro-and/or macroangiopathy consequences at the time of diagnosis. Diabetes